---
title: Safety and efficacy of odronextamab in patients with relapsed or refractory
  follicular lymphoma
date: '2024-08-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39147364/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240816182134&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Odronextamab achieved high complete response rates with
  generally manageable safety in patients with heavily pretreated R/R ...'
disable_comments: true
---
CONCLUSIONS: Odronextamab achieved high complete response rates with generally manageable safety in patients with heavily pretreated R/R ...